Life Sciences Times

PepGen Reports $17.8 Million Q2 Loss as Higher-Dose DM1 Trial Advances

Sarepta Reports $401.3 Million in Q2 Revenue, Names Michael Severino CEO

Zai Lab Reports $50.8 Million Q2 Loss as Drug Pipeline Advances

FDA Approves Takeda’s ORZEYFUL for Narcolepsy Type 1

Amylyx Reports $43.4 Million Q2 Loss as Phase 3 Avexitide Data Near

Vedanta Biosciences Raises $60 Million to Advance Phase 3 C. Difficile Trial

Scholar Rock Reports $109.9 Million Q2 Loss as FDA Reviews SMA Drug

Wolters Kluwer Says UpToDate Expert AI Adopted by About 2,500 U.S. Hospitals

Myomo Raises 2026 Revenue Outlook as Q2 Sales Rise 21 Percent

Ono Pharma, Mediar Therapeutics Partner on Antibody Drugs for Fibro-inflammatory Diseases